Shinhung (004080) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Shinhung KRW 5,063, price KRW 14,650, upside -65.4%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shinhung for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 12,510 KRW – 16,755 KRW · fair‑value band 3,544 KRW – 5,879 KRW · the 14,650 KRW price screens above the 5,063 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Shinhung in your weekly email
Every Wednesday you see whether Shinhung is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shinhung Co., Ltd. manufactures, imports, and sells dental products and supplies in South Korea.
Show more
Shinhung Co., Ltd. manufactures, imports, and sells dental products and supplies in South Korea. Its products include implant systems; dental units and chairs; dental alloys, such as composition tables, crowns, and porcelain under the Goldenian brand name; prefabricates SS crowns; taurus, insert, and mobile cabinets; compressors and mixers; dental needles; dental porcelain powder and laboratory products; and disposable needles, dental operatories, and autoclaves and X-ray equipment. The company also offers loan services for dentists. Shinhung Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
Stock analysis
Shinhung (004080) currently trades at 14,650 KRW, while our model-based Fair Value estimate is 5,063 KRW, implying the stock looks roughly 189.4% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 8,347 KRW per share, and 1 of the 15 models we run sit above the 14,650 KRW price.
Bear case: the Dividend Discount group reads lowest at 2,064 KRW, and 14 of the 15 models stay below the price. Evidence for this calculation is medium.
Scenario range: 3,544 KRW (bear) to 5,879 KRW (bull), the price of 14,650 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Shinhung reported revenue of 103B KRW in FY2025 versus 127B KRW in FY2021, a compound −5.2%/yr. Reported net income was 2.8B KRW in FY2025, compounding −32.3%/yr from FY2021.
Key figures
Market cap 138B KRW (≈ $102M) · P/S ratio 1.25 · Dividend yield 2.5% · Net margin 2.8% · Return on equity 3.0% · Return on assets (EBIT) 6.8% · Operating margin 3.2% · Revenue (TTM) 104B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 12% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −65%, 004080 screens richer than that median.
Fair Value models
Bear 3,544 KRWFair Value 5,063 KRWBull 5,879 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.12/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Start year 2020 (pandemic). Over 10 years: −2.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+20.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.8%
Dividend (yield on the price)2.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 7%
⚠ Revenue per share shrinking 2.6%/yr over ~6Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Above median
Fair Value upside−65% · Bottom 25%
Profitability
Return on equity (TTM)3% · Above median
Return on assets3% · Above median
Net margin (TTM)3% · Below median
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth7% · Above median
Dividend yield (TTM)2.5% · Above median
Balance sheet
Debt / equity0.02× · Below median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)33· sector 31
PAST (return on equity)12· sector 7
HEALTH (low debt)99· sector 97
DIVIDEND (yield)49· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shinhung Fair Value". https://www.fairvalue-calculator.com/stock/004080
Frequently asked questions
Is Shinhung (004080) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 5,063 KRW versus a price of 14,650 KRW, about −65% upside (overvalued).
What is the fair value of 004080?
Our model-based fair value for Shinhung is 5,063 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 14,650 KRW.
What is the quality score of 004080?
Shinhung has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shinhung (004080)?
Our model-based price target is the fair value of 5,063 KRW (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 3,544 KRW, optimistic scenario 5,879 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Shinhung stock forecast for 2026?
Our models put fair value at 5,063 KRW, about −65% upside versus a price of 14,650 KRW (overvalued). Cautious scenario 3,544 KRW, optimistic scenario 5,879 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Shinhung (004080)?
Shinhung reported trailing-twelve-month revenue of about 104B KRW (latest available figure, as of Sep 24, 2026).
Does Shinhung pay a dividend?
Shinhung currently shows a dividend yield of about 2.46% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Shinhung (004080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shinhung it is 5,063 KRW per share (as of Sep 24, 2026), against a price of 14,650 KRW. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Shinhung stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 004080 trades above its calculated fair value: price 14,650 KRW, fair value 5,063 KRW, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 004080?
No. The price is what the market pays today (14,650 KRW); the fair value is what the company's own numbers justify (5,063 KRW). For Shinhung the two are 9,587 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Shinhung worth?
The market values Shinhung at about 138B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 14,650 KRW; our models calculate a fair value of 5,063 KRW per share.
What do the bullish and bearish scenarios say about 004080?
Our models span a range for Shinhung: cautious scenario 3,544 KRW, base 5,063 KRW, optimistic 5,879 KRW per share (as of Sep 24, 2026, price 14,650 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shinhung (004080)?
Balance-sheet figures for Shinhung (as of Sep 24, 2026): return on equity 3.0%, debt of 0.02 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 004080 from its 52-week high?
Shinhung trades at 14,650 KRW, at its 52-week high of 14,700 KRW and 12% above the low of 13,027 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 5,063 KRW is for.
Which stocks are comparable to Shinhung?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shinhung stock attractive at the current price?
The data as of Sep 24, 2026: price 14,650 KRW, calculated fair value 5,063 KRW (−65%), Quality Score 51/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 004080 calculated?
We run Shinhung through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 5,063 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Shinhung itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shinhung (004080)?
The closing price on Sep 23, 2026 was 14,650 KRW. Our model-based fair value is 5,063 KRW, about −65% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shinhung right now?
The price sits above even our optimistic bull case (5,879 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Shinhung
How large is the market capitalisation of Shinhung (004080)?
The market capitalisation of Shinhung is 138B KRW (≈ $102M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shinhung (004080)?
The price-to-sales ratio of Shinhung is 1.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Shinhung (004080)?
The dividend yield of Shinhung is 2.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shinhung (004080)?
The net margin of Shinhung is 2.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shinhung (004080)?
The return on equity (ROE) of Shinhung is 3.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shinhung (004080)?
On an EBIT basis the return on assets of Shinhung is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shinhung (004080)?
The operating margin of Shinhung is 3.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shinhung (004080)?
Revenue at Shinhung is growing +6.5% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shinhung (004080)?
Earnings per share at Shinhung are growing +177% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shinhung (004080) generate?
The free cash flow of Shinhung is −1.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shinhung (004080) carry?
The net debt of Shinhung is 8.9B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Shinhung in the live analysis
One click puts Shinhung on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
